knowledge -WSS

knowledge

author：focus 2025-09-30 00:34:55 - browse：986

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Appeals court upholds limits to abortion pill

hotspot

focus

WSS

How Long Island became the ‘eugenics capital of the world’

The inclusion problem at the heart of rehabilitation research

Future doctors need a strong humanities education

Future doctors need a strong humanities education

Complete sequence of Y chromosome published for first time

Medicare drug price lawsuits could be good politics for Biden

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Neuroscience startup Neumora files for IPO

Malaria cases in Florida and Texas: Here’s what you need to know

AstraZeneca bets AAV gene therapy will still deliver the goods

Heart attack and stroke risk calculators need revising

What do new weight loss drugs mean for bariatric surgery?

Hepatitis C has a cure — but many Americans still lack access to it

How a symptom of dementia informs our understanding of creativity

Guidelines to prevent youth baseball injuries need more muscle

How Long Island became the ‘eugenics capital of the world’

explore

AstraZeneca bets AAV gene therapy will still deliver the goods

How to make AI work for medicine

In science, is the line between industry and academia shifting?

Head of FDA's diagnostics center, who led through Covid, retires

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

FDA sets aggressive timeline for overhauling inspection procedures

hotspot

focus

focus

Wikipedia